Treat Regimen

DRUG3 trials

Sponsors

Chong Kun Dang Pharmaceutical, Second Affiliated Hospital, School of Medicine, Zhejiang University, Wen-zhao ZHONG

Conditions

Breast CancerLeucogenMyeloma, MultipleNeutropenia (Low White Blood Cell Count)Nonsmall Cell Lung CancerRibociclib

Phase 1

CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma

Chong Kun Dang PharmaceuticalMyeloma, Multiple

Start: 2017-05-10End: 2021-09-30Target: 18Updated: 2020-02-24

Phase 2

the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer

RecruitingNCT07380646

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityBreast Cancer, Leucogen, Neutropenia (Low White Blood Cell Count) +1

Start: 2026-01-07End: 2028-06-01Target: 94Updated: 2026-04-30

Unknown Phase

Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC

RecruitingNCT07626736

Wen-zhao ZHONGNonsmall Cell Lung Cancer

Start: 2025-12-01End: 2028-12-31Target: 300Updated: 2026-06-04